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ABSTRACT: Fourier transform-infrared spectroscopy (FT-
IR) represents an attractive molecular diagnostic modality for
translation to the clinic, where comprehensive chemical
proﬁling of biological samples may revolutionize a myriad of
pathways in clinical settings. Principally, FT-IR provides a
rapid, cost-eﬀective platform to obtain a molecular ﬁngerprint
of clinical samples based on vibrational transitions of chemical
bonds upon interaction with infrared light. To date,
considerable research activities have demonstrated compet-
itive to superior performance of FT-IR strategies in
comparison to conventional techniques, with particular
promise for earlier, accessible disease diagnostics, thereby
improving patient outcomes. However, amidst the changing
healthcare landscape in times of aging populations and
increased prevalence of cancer and chronic disease, routine adoption of FT-IR within clinical laboratories has remained
elusive. Hence, this perspective shall outline the signiﬁcant clinical potential of FT-IR diagnostics and subsequently address
current barriers to translation from the perspective of all stakeholders, in the context of bioﬂuid, histopathology, cytology,
microbiology, and biomarker discovery frameworks. Thereafter, future perspectives of FT-IR for healthcare will be discussed,
with consideration of recent technological advances that may facilitate future clinical translation.
The potential of infrared (IR) spectroscopy as a powerfulclinical tool is abundantly clear as demonstrated from the
myriad proof-of-principle studies boasting high speciﬁcity and
sensitivity for disease detection and classiﬁcation.1−9 There is
an ever present search to develop novel, low-cost, and rapid
diagnostics platforms to prevent bottlenecks in healthcare
workﬂows and subsequently time delays in patient care, the
ramiﬁcations for which are poorer patient outcomes and huge
economic burdens upon healthcare institutions.10−12 Addi-
tionally, aging populations and increased burden of chronic
disease demand greater diagnostic throughput capabilities to
diagnose and stratify patients given the number of people aged
over 65 is predicted to swell by 71% by year 2050 in developed
nations.13 The future implementation of IR spectroscopic
techniques extends to, and may redeﬁne, numerous stages of
clinical management from screening all the way through to
treatment monitoring.14 It is versatile in the clinical
applications due to the ability to discriminate individual IR
active molecular species making both unianalyte and multi-
analyte observation possible. Samples are interrogated using an
infrared beam by stimulating intermolecular bond vibrations
which, depending on the particular molecular bonding
environment, will selectively absorb speciﬁc infrared wave-
lengths in accordance with Beer−Lambert’s law.15 From this, a
multitude of clinically relevant biomolecules can be quickly
and accurately identiﬁed and quantiﬁed for disease diag-
nosis.16,17 Furthermore, sophisticated multivariate analysis
techniques can be employed to discriminate between patient
disease states and provide comprehensive biomolecular
“ﬁngerprint” proﬁles from a variety of patient sample
types.1,7,18−20 All of this has been demonstrated on a wide
range of biological sample types, such as bioﬂuids, cells, and
tissues.1,15,21−24
Infrared spectroscopy is generally posited as being simple to
operate, requiring no reagents, inexpensive, noninvasive, and
nondestructive14 and as such is already utilized in an expansive
range of applications such as in the pharmaceutical, food,
environmental, and forensics industries. It should be obvious,
then, that there is a place for IR spectroscopy in the clinical
environment which raises the question as to why clinical
translation has been so elusive? The aims of this Perspective is
to assess the suitability and highlight future directions of
infrared spectroscopy within speciﬁc clinical situations from
the perspective of spectroscopists, clinicians, and ﬁnancial
contributors.
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■ DEVELOPING THE TRANSLATION
Demonstrating potential as a powerful clinical tool does not
necessarily demonstrate clinical suitability. It should be
understood that successful translation of a technology into
healthcare pathways requires more than simply being able to
inform clinical decisions. Clinical translation is, in large part, an
entrepreneurial endeavor and not only a humanitarian one. It
can therefore appear a daunting and ambitious undertaking
requiring proﬁciency outwith the typical spectroscopists ﬁeld
of expertise, especially when considering the large amount of
time such a project can consume.25 Development of a medical
device is a project in communication not only within the
research team but with contacts from a broad range of
disciplines including intellectual property (IP) law, health
economics, manufacturing, assembly, distribution, sales and
marketing, and healthcare professionals.
Translation of IR spectroscopy is by and large progressed by
“technical push” rather than “clinical pull”, whereby existing
spectroscopic technologies are being adapted in order to enter
the clinical market.14 This means the technology in its current
form may not be suitable for the clinic for a variety of reasons,
such as by not being user-friendly, disrupting clinical
workﬂows, cost, lab footprint, and incompatibility with
automation. These are absolutely valid reasons to be hesitant
about adopting new healthcare technologies as the ramiﬁca-
tions for disrupting clinical workﬂows, for example, should not
be underestimated. Continued end user (e.g., clinicians,
laboratory technicians, etc.) input and support is incredibly
valuable in this regard as in-depth knowledge of the clinical
environment is the best way to resolve issues during
development stages and achieve the most market ready
product as possible before embarking on clinical trials.
However, spectrometer instrument manufacturers will not
substantially modify their products for a clinical environment
because it is not a market they are established in and therefore
view expansion into this market as a signiﬁcant risk.26
Conﬁrming the existence of a consumer base through
thorough examination of an unmet clinical need, proof-of-
concept studies and ﬁnancial projections via health economics
analysis is a good way to reassure manufacturers that tailoring
their instruments toward clinical applications will help the
growth of their own company. An example of this can be seen
with Glyconics, a Cambridge based IR diagnostics company,
working with Spectrolytics, a German IR spectrometer
development and supply company, who together are producing
a hand-held point-of-care (POC) FT-IR device speciﬁcally for
use in a clinical setting. Through this partnership, Glyconics
are commencing a major clinical trial in Q1 of 2019 to validate
claims that the device can be used to diﬀerentiate chronic
obstructive pulmonary disease (COPD) from other disease
states and also monitor the conditions progression.27,28 This is
a signiﬁcant step on the road toward clinical translation and
would not have been possible without a mutually beneﬁcial
relationship between medical diagnostic IR spectroscopy
experts and instrument developers. Clinspec Diagnostics Ltd.,
a spin−out from the University of Strathclyde, present another
example of the impending clinical translation of FT-IR
technology. They recognized through proof-of-concept studies
that attenuated total reﬂection-Fourier transform-infrared
(ATR-FT-IR) could be used to identify and classify brain
cancers from blood serum samples.1 The company then
undertook a health economics study where they collaborated
with clinical experts and health economists to inform economic
models investigating the cost and health beneﬁts an ATR-FT-
IR serum based triage tool could have when implemented into
brain tumor healthcare pathways. The study predicted that the
test had a high probability of being cost-eﬀective and
improving the Quality Adjusted Life Years (QALYs) of brain
tumor patients within the NHS.29 This helped ClinSpec
Diagnostics Ltd. secure signiﬁcant funding for further develop-
ment. This is an emblematic example of why protection of IP
and a health economics assessment should be carried out as
soon as possible when identifying that a nonclinical technique
has potential value for a speciﬁc clinical application. In simple
terms, a health economics study will help elucidate the answers
to two vitally important questions: (1) Will the proposed
technique improve patient outcomes? (2) Will it alleviate
ﬁnancial strains imposed on healthcare systems while
generating revenue? Conﬁdence in satisfying both conditions
is invaluable toward gaining clinical support and informing
investment decision. There are other stand out examples of
translational research of IR spectroscopic techniques. Biotech
Resources, whose founding members have received interna-
tional acclaim for their work using ATR-FT-IR to screen
malaria in low-income areas,8 were granted large amounts of
investment from the Australian government toward develop-
ment of a rapid FT-IR based diagnostic platform for the
detection of blood borne pathogens associated with sepsis.
Cireca Theranostics have developed “spectral histopathology”
protocols for reagent free objective, machine learning based
analyses of tissue sections for use in situations where
histopathologists cannot reach an agreement of how to classify
a sample.30,31 These promising enterprises along with a strong
mutual desire from both researchers and clinicians to inform
healthcare decision making with state-of-the-art analytics
indicates imminent arrival of IR spectroscopy to the clinical
environment. A versatile array of techniques makes IR
spectroscopy relevant to a wide variety of clinical applications
and thereby an attractive opportunity to investors provided the
appropriate evidence is clearly demonstrated to all concerned
parties.
■ IR SPECTROSCOPY OF BIOFLUIDS
Bioﬂuids are irrefutably a high value diagnostic resource due to
their ease of collection with minimal invasiveness and the
abundance of biochemical information contained within and
are perhaps the most eﬀective means to carry out objective,
cost-eﬀective, and rapid diagnosis and triaging of patients.32
However, the procedures from sample collection to results
delivery are hugely diverse depending on the target molecule
or molecular signature. Multiple physical operations and
chemical reactions may have to be carried out before the
target molecule can be quantiﬁed. Compound this with the
amount of parallel processes required to test for several
biomolecules within each sample across several patients and it
is clear how labor intensive and susceptible to errors clinical
chemistry can become. Modern clinical laboratories are
conﬁgured to handle this problem, though, through clever
automation devices and systems,33 but infrared spectroscopy
oﬀers a diﬀerent perspective on how to combat this issue. Since
infrared spectroscopy captures a biochemical signature of all
the bonding environments present within the sample, it follows
that the resultant data set is inﬂuenced by all the samples’
constituent molecules which are therefore detectable and
quantiﬁable. Many infrared spectroscopy proof of concept
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studies have already established that a wide variety of clinically
signiﬁcant ﬁndings can be retrieved from a range of bioﬂuids
such as serum,34 plasma,35 whole blood,36 sputum,37 bile,2
amniotic ﬂuid,38 cerebrospinal ﬂuid,39 urine,40 saliva,41 and
even tears.5 The utility of IR spectroscopy in the clinic extends
beyond a univariate approach with the implementation of
multianalyte pattern recognition algorithms for disease
detection and the potential to discover novel bio-
markers.19,42,43 Indeed, spectroscopic bioﬂuid analysis could
be used to inform clinical decisions by providing a
comprehensive biochemical panel as well as indicating the
likelihood of the presence of speciﬁc diseases, from cancers to
chronic or infectious disease.3,9,18,44−48 Sepsis diagnosis is one
such condition where not only do the causal pathogens need to
be identiﬁed, but biomarker concentrations, such as lactate and
c-reactive protein, are important in stratifying patients and
determining clinical actions.49 Blood cultures are the current
gold standard for determining the presence of infection in the
blood but take up to several days to return results while the
host’s condition deteriorates.50 Researchers at Monash
University, Australia, are currently addressing this unmet
clinical need by developing methods of detecting blood borne
pathogens using ATR-FT-IR on aqueous blood ﬁlms with the
aim of delivering results at the point-of-care.51,52
Infrared spectroscopy faces a variety of obstacles to
overcome when analyzing biological materials and even more
technologies and protocols have been developed to overcome
them.15 The speciﬁc bioﬂuid being analyzed will inﬂuence the
preanalytical treatment protocols, the FT-IR mode selected
(transmission, transﬂection, or ATR), the light source used
(globar, QCL, or synchrotron), and the detector used (focal
plane array, linear array, or single element). Each of these
choices maintain strengths and weaknesses, so careful
consideration is required for speciﬁc clinical applications. For
more information on FT-IR sampling considerations, please
refer to an in depth protocol by Baker et al.15 Bioﬂuids in
particular have a high water content that absorbs IR light
strongly in the mid-IR region and may contain cellular
components that give rise to dispersion eﬀects.53 Water
absorption obscures pertinent information on other bio-
markers present in the sample, and so there are almost always
eﬀorts made to eradicate the water contribution of bioﬂuids.
This is usually done by drying samples directly upon the
sampling site, but homogeneous sample distribution is diﬃcult
due to the “coﬀee-ring” eﬀect that concentrates large molecular
weight molecules in a concentric ring around the droplet
deposition site.54,55 Nevertheless, plenty of proof-of concept
studies show excellent results using this method,1,9,34,56
although drying times and methods have not been stand-
ardized. Hands et al. have shown that ATR-FT-IR can analyze
dried blood serum ﬁlms to discriminate between patients with
brain cancer and noncancer controls with sensitivity and
speciﬁcity of 91.5% and 83%, respectively.57 An earlier study
did, however, highlight the time limiting factor created by the
need to individually dry samples upon the sampling site for
analysis before another sample can be prepared.1 This would
create an obvious bottleneck in clinical workﬂows and is a
technical issue that needs to be overcome before ATR-FT-IR is
suitable for the clinical environment. More recently, an
advanced sample spotting technique called piezo-jetting,
which deposits discrete arrays of tiny (∼130 μm) sample
droplets, has been used in conjunction with QCL on serum
samples with comparable reproducibility and diagnostic power
as the aforementioned study by Hands et al.1,58 More
importantly, drying and acquisition time was signiﬁcantly
reduced, and the use of QCL light sources may better lend
itself to POC diagnostics and is more capable at detecting low
concentrations of analyte compared to conventional FT-IR
techniques.59 All are signiﬁcant factors that will progress
toward clinical translation. Interchangeable disposable silicon
IREs60 could be used as the central mechanism around which
an automated high-throughput ATR-FT-IR system could be
constructed, although issues of signal loss due to signiﬁcant
beam attenuation through the silicon crystal would need to be
addressed.61 Mitchell et al.32 assert that a vibrational
spectroscopy based POC device presents an attractive option
for an objective, low-cost bioﬂuid screening platform. They go
on to propose hypothetical designs of a hand-held FT-IR POC
device (Figure 1a) that employs microﬂuidic separation of
blood into its derivatives (plasma/serum) with remote
classiﬁcation for continuous bedside monitoring. Mitchell
even suggests that a user-friendly “traﬃc-light” system could
be used to further speed-up triaging decisions where green
would indicate no disease, yellow cause for further screening,
and red the presence of disease. This design may be perfectly
complemented by lab-on-a-chip technology developed by
Schwarz et al.62 who have miniaturized QCL, waveguide, and
detector into a monolithically integrated mid-IR molecular
sensing platform (Figure 1b) that can be fully submerged in
liquid samples. Two major technical developments permitted
this design. The ﬁrst is a bifunctional quantum cascade laser/
detector (QCL/D) that can act as both light source and
Figure 1. (a) Concept drawing shows blood separated into serum and plasma derivatives for simultaneous ATR spectral analysis, the results from
which are wirelessly communicated to centralized data systems for classiﬁcation. (b) Miniaturized QCL/D with an SPP waveguide provides an ideal
sensing stage for mid-IR microﬂuidic devices.
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detector depending on the applied bias. The second is a surface
plasmon polariton (SPP) waveguide comprised of a narrow
dielectric stripe (silicon nitride) printed atop an unpatterned
gold layer. This constrains the mid-IR plasmon waves with
high-coupling eﬃciency of the beam from emitter to receiver
while also promoting strong interaction with the analyte. An
evanescent decay that can range from 2 to 50 μm in length can
be achieved depending on the thickness of SiN layer. This
rather elegant single-chip system is a low-cost IR spectroscopic
platform that may prove ideally suited to bioﬂuid screening
applications pending further investigation.
Aside from the multitude of technical milestones that are
being surpassed and investigated, there are preanalytical
bioﬂuid sample handling and treatment considerations that
need to be standardized.55 Bioﬂuids likely to contain
micrometer scale structures such as whole blood, for example,
that is usually fractionated so that the derivatives, serum or
plasma, may be analyzed. This is because micrometer scale
structures, like erythrocytes (∼8.2 μm), are of sizes that match
the wavelength of infrared light (2.5−25 μm) will result in
dispersion artifacts, such as Mie scattering, in the acquired
spectra.63 One minor complication in handling is in storage.
Bioﬂuids are either analyzed fresh or stored frozen (−80 °C),
incurring an added complication since variance may be
introduced through repeat freeze−thaw cycles, which should
be avoided where possible.64 Bioﬂuids may also be fractionated
to partition high molecular weight (HMW) molecules from
low-molecular weight molecules (LMW) so that each fraction’s
constituent molecules are less obfuscated by spectral
contributions from each other.40 For instance, Bonnier et
al.16 were able to improve the precision and accuracy of
quantitative models for estimating glucose concentrations in
spiked serum samples by eliminating the HMW component of
the samples prior to spectral analysis. This technique may help
overcome the FT-IR limitation of being unreliable at
measuring low molecule concentrations by removing compet-
ing molecular signatures. It is evident from the literature
described here that there are a multitude of projects underway
to tailor IR spectroscopic techniques and processes for bioﬂuid
analysis and move much needed technologies toward clinical
suitability.
■ INFRARED SPECTROSCOPY FOR
HISTOPATHOLOGY
Histopathological evaluation of clinical tissue samples is
fundamental to the diagnosis, prognosis, and treatment of
medical conditions, including cancers, where morphological
features of neoplasms facilitate detection of malignancies and
elucidation of tumor grades. Today, clinical histopathological
practice remains predominantly unchanged since its inception
over 100 years ago and primarily concerns microscopic
examinations of formalin-ﬁxed, paraﬃn-embedded (FFPE)
tissue sections, where hematoxylin and eosin (H&E) stains
provide necessary contrast for visual inspection of tissue
architectures. Consequently, histopathology is intrinsically
subjective with signiﬁcant reported inter- and intraoperative
variability,65,66 especially for disease stratiﬁcation of tumor
subclasses.67 Additionally, biopsies are often restricted to
clinically assigned areas of interest, due to inherent time
restrictions of laborious sample preparation and analytical
procedures, which may inadvertently lead to mischaracteriza-
tion of heterogeneous tumors.68 Recently, concurrent use of
immunohistochemistry has enabled speciﬁc identiﬁcation of
molecular biomarkers associated with cancer pathogenesis,
thereby providing much needed molecular content on samples
and improving clinical diagnosis. However, immunohistochem-
istry is synonymous with antibody reagents that are notoriously
expensive, limit the scope of molecular analysis to available
antigen−antibody aﬃnity based interactions, and restrict
applicability to a single protein biomarker for a given clinical
tissue section.69 In times when worldwide new cancer cases are
projected to rise to ∼26 million annually by 2030,70 with
pathologists spending vast amounts of time evaluating
noncancerous samples,71 amidst escalating economic strain
on health care resources, it is pertinent to explore emerging
modalities for clinical translation to assist future histopathology
laboratories.
Spectral histopathology describes the coupling of conven-
tional mid-infrared FT-IR/Raman technologies with optics
where projections of infrared light at 2−14 μm wavelengths on
to clinical tissue sections permit identiﬁcation of spatially
resolved spectroscopic transitions indicative of the chemical
composition of sample constituents. Spectral histopathology
represents an attractive molecular based imaging technology
for translation to clinical histopathology laboratories, where
complete clinical sample sections may be chemically proﬁled in
a nondestructive manner without the requirement for stains,
antibodies, and secondary labeled reagents.72 Hence, hetero-
geneous samples may be classiﬁed according to unique
biochemical signatures of cell types and molecules arising
from nucleic acid, lipid, protein, and carbohydrate contribu-
tions,15 thereby, providing additional diagnostic information
on tissue sections. Moreover, spectral histopathology has no
additional sample preparation requirements and permits
analysis of dewaxed and paraﬃn embedded tissue73 and thus
represents an ideal candidate for integration in to current
histopathological practice.
Spectral histopathology has demonstrated through proof-of-
principle studies immense potential for clinical translation and
integration with histopathological laboratories, with sensitive
and speciﬁc diagnosis demonstrated for several neoplastic
tissues, from lung21 to breast cancers.22 Yet, major barriers to
clinical translation persist, both regarding technical spectro-
scopic and clinically orientated challenges, which must be
surmounted if routine adoption of spectral histopathology is to
be realized in health care settings.
One of the major perceived barriers to clinical translation is
spectral acquisition time for clinical tissue samples. Today,
clinical histopathology departments analyze hundreds of
samples per day consisting of tissue sections of 1−5 μm
thickness mounted to standard glass 75 mm × 25 mm
microscope slides. Consequently, current tissue volumes
employed for clinical diagnosis present a major obstacle for
spectroscopic translation, where single point mode analysis of
tissue with single element detectors is intrinsically slow and
time prohibitive for clinical translation.74 Recently, emergence
of focal plane array detectors has transformed spectral imaging
capabilities for the clinic, where collection of thousands of
spectra concurrently enables substantial reduction in spectral
acquisition times.73 Still, spectroscopic interrogation of large
tissue sections may take several hours,75 which restricts clinical
sample throughput. Alternatively, emergence of tissue micro-
arrays whereby multiple tissue cores of submillimeter diameter
positioned on single microscope slides from diﬀerent clinical
regions of interest may facilitate high-throughput spectral
histopathology, as recently demonstrated for prostate cancer-
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ous tissues.76 However, there remains a trade-oﬀ between
acquisition time and tissue volume, where reduced representa-
tion of samples may promote mischaracterization of hetero-
geneous tumors.77 Hence, this poses a critical question as to
the optimum method from a time perspective for clinical
translation, including whether collecting information over the
entire mid-infrared wavenumber region is conducive to
translation or entirely necessary for accurate diagnosis?
Recently, emergence of quantum cascade lasers (QCLs) has
revolutionized the potential for translation of spectral
histopathology, which project discrete frequencies of infrared
light rather than entire continuous mid-infrared spectra.
Hence, QCLs may solely probe molecular biomarkers
pertinent to clinical diagnosis as opposed to the complete
chemical constituents of tissue samples,78 which has dramatic
implications for analysis time and represents a paradigm shift
for clinical implementation of spectral histopathology.
Another perceived technological hurdle for clinical trans-
lation of spectral histopathology concerns whether spectral
images contain suﬃcient physiological detail to inform diﬃcult
clinical diagnosis. Today, optical microscopy for histopathol-
ogy is limited by the diﬀraction limit of visible light, with
optimum spatial resolution capabilities of 0.2 μm that can
discern small subcellular details pertinent for early cancer
diagnosis.79 Conversely, spectral histopathology is restricted by
the diﬀraction limit of infrared light, with optimum spatial
resolutions of 2.5 μm in the clinically important ﬁngerprint
region.73 Yet, conventional FT-IR spectrometers rarely operate
at such resolution to achieve adequate signal-to-noise and
overcome inherently noisy Globar sources, making inspection
of subcellular details diﬃcult.73 However, new infrared sources,
such as QCLs, free electron lasers, and super continuum
sources, allow excellent signal-to-noise and diﬀraction limited
resolutions69 and may facilitate future routine inspection of
small subcellular features. Although contact modalities such as
AFM-IR may overcome the diﬀraction limit of infrared light,80
current techniques are time and cost prohibitive for near future
clinical translation, and therefore understanding current
spectral imaging capabilities in a clinical context is paramount
for successful integration into health care.
A major barrier from a clinical perspective for translation of
spectral histopathology is how can such technology be
implemented in an economically viable manner without
disrupting current histopathology practices. Currently, histo-
pathology is performed on glass microscope slides, which are
not transparent over the entire mid-infrared frequency range,
limiting the acquisition of biological information from tissue
sections.81 Hence, adoption of spectral histopathology may
require implementation of diﬀerent analytical substrates, either
barium or calcium ﬂuoride for transmission or reﬂective coated
slides for transﬂection experiments, which have their own
limitations for clinical translation. Speciﬁcally, barium and
calcium ﬂuoride substrates incur costs of ∼£60 per slide and
do not permit automatic handling due to poor mechanical
properties, while reﬂective coated slides suﬀer from spectral
artifacts arising from the standing wave eﬀect, further
exacerbated by variation in sample thickness.73 Therefore,
such limitations pose critical questions as to whether it is
economically and practically viable to propose shifts from glass
microscope slides in histopathology and must be clearly
demonstrated before clinical translation can be realized.
Similarly, another critical clinical question concerns how
medical staﬀ would interpret vast amounts of spectral data?
Bhargava’s group recently demonstrated the potential of
stainless staining where biological signatures obtained from
spectroscopic interrogation of normal breast, precancer,
nonmalignant, and malignant tissue microarrays were
computationally transformed to represent classical staining
results for familiar interpretation by clinicians.72 In particular,
Mayerich showed that computational staining from infrared
spectra had competitive to improved diagnostic performance in
comparison to both classical H&E dyes and speciﬁc
immunohistochemical stains, including Masson’s trichrome
stain, high molecular weight cytokeratin, smooth muscle alpha
actin, and vimentin (Figure 2). Hence, infrared spectroscopy
has the capacity to obtain a vast array of biomarkers from
clinical tissue sections presented in an accessible, digital format
for clinical observation and is an important example of how
spectroscopy must provide integrated platforms to compliment
current clinical practices. Lastly, the wide scope of current
research activities in spectral histopathology must converge
and agree on a consensus for standardization protocols for
diﬀerent tissue specimens and will be crucial to achieve clinical
translation of spectral histopathology.
■ INFRARED SPECTROSCOPY FOR
CYTOPATHOLOGY
Infrared spectroscopy is a proven analytical tool for
investigation of eukaryotic cells that has considerable potential
for clinical translation to cytopathology to assist diagnosis of
precancerous, cancerous, and infectious diseases. Cytopathol-
ogy concerns the optical evaluation of stained cell
morphologies through microscopic assessment of ﬁxed or
suspended cells. Cytopathology has revolutionized early
detection of certain cancers including cervical cancer in the
developed world, where high-volume Papanicolau (Pap)
screening of exfoliated cells ﬁxed to glass microscope slides
permits inspection of cellular abnormalities indicative of cancer
pathogenesis, contributing to 70% reductions in mortality in
England.82 However, the subjective nature of Pap screening
produces test sensitivities as low as 55.4%,83 which may cause
Figure 2. Tissue microarrays (TMAs) representing either normal
breast tissue, precancer, nonmalignant, and malignant breast cancer
samples. Comparison of three physical (left) and computational
(right) stained samples from (a) H&E stains, (b) Masson’s trichrome
stain, (c) high-molecular weight cytokeratin, (d) smooth muscle alpha
actin, and (e) vimentin. Each spot is 1.4 mm diameter.
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signiﬁcant proportions of cervical cancer patients to receive
false negative results, and is responsible for 29.3% of clinical
errors that lead to development of preventable invasive cervical
cancer.84 Consequently, Pap testing is now routinely
performed in conjunction with HPV testing which has been
shown to have greater sensitivity; however, the diagnostic
procedure is recognized to be costly, be time-consuming, and
has lower speciﬁcity.85,86 Furthermore, only 58.6% of Pap test
results were anticipated to reach recipients within a 2-week
time frame in 2017−2018, despite national policies stating that
all women should receive test results within this period.87
Hence, there is a clear clinical need for low-cost, high-
throughput, molecular based tests to assist cancer-screening
programs in stretched cytopathology departments.
Infrared spectroscopy has demonstrated promise for
detection of cervical neoplasia with observation of distinct
spectral biochemical signatures pertinent to clinical diagnosis.
Speciﬁcally, Cohenford found changes in the shape and
intensity of amide I, amide II, and symmetric and asymmetric
phosphate and glycogen vibrations were associated with
dysplasia and squamous cell carcinoma diagnosis,24 with
spectral features since conﬁrmed by other groups.88 Similarly,
Schubert showed that infrared spectroscopy may detect the
presence of HPV infected cells that arise from further changes
in DNA, RNA, and ν(CH) vibrational modes.89 Additionally,
Ostrowska demonstrated that spectral changes associated with
expression of protein biomarker p16INK4A could be employed
to further discriminate between negative HPV-C33A and
positive HPV-16/18 copy numbers, thus providing additional
information for clinical diagnosis of cervical cancers.90
Yet, translation of infrared spectroscopy to clinical
cytopathology is largely elusive, which poses critical questions
as to why such a promising technology has not so far been
integrated into the clinic? First, studies mentioned above have
been conducted on small sample populations, and the
technology must be further validated with large clinical trials
to demonstrate clinical eﬃcacy and establish comparable
sensitivities and speciﬁcities. Furthermore, some studies
mentioned above have been conducted on calcium ﬂuoride
substrates, which are cost prohibitive for clinical translation
especially in the context of high volume testing. Recently,
Wood demonstrated successful spectral distinctions for
diﬀerent stages of squamous cervical epithelium on reﬂective
coated substrates costing $1 per slide,91 and although cost
savings are made from the absence of stains, such substrates are
still signiﬁcantly more expensive than standard glass micro-
scope slides. Therefore, future health economic studies must
be conducted to prove cost-eﬀectiveness of such techniques
before clinical translation can be realized for cancer screening.
Conversely, Neves employed ATR-FT-IR spectroscopy for
discrimination between healthy cells and squamous intra-
epithelial lesions from blood plasma samples with clinically
competitive sensitivity and speciﬁcity, negating the need for
calcium ﬂuoride or reﬂective coated substrates.23 However, the
study utilizes a diamond internal reﬂection element, which is
inherently expensive and limits analysis to sequential sample
measurements, with 30 min drying times for each sample not
conducive to high-throughput clinical cytology. Therefore, this
highlights the need for critical consideration of cytopathology
environments and of the requirement for minimal disruption of
new technologies to current cytopathology laboratories.
To this extent, another critical question for clinical
translation of infrared spectroscopy to cytopathology is
whether the technology can be implemented into clinical
laboratory workﬂows without major disruption? Proposed
approaches of integrated cytological and infrared spectroscopic
analysis would require cell samples to be examined
spectroscopically following inconclusive cytopathology inspec-
tions. However, hematoxylin, eosin, and Pap stains currently
employed for cytological investigations were found to inﬂuence
spectral signatures of cells, with an additional band at 1305
cm−1 and reduced intensities at 1740, 2850, and 2920 cm−1
attributed to exogenous stains and staining procedures,
respectively.92 While it was found that spectral signatures of
staining did not compromise diagnostic capabilities for
detecting lung cancer cells, the study employed a synchrotron
light source with signiﬁcantly improved spatial resolution over
infrared sources conceivable for the clinic.93 Therefore, large-
scale studies must be conducted to assess clinical viability of
spectroscopic interrogation of stained cytology samples with
conventional FT-IR instrumentation. Furthermore, if there is
no clinical appetite or clear demonstration of cost-eﬀectiveness
concerning employment of reﬂective coated slides for spectral
cytology, spectroscopists must explore novel strategies to work
with standard glass microscope slides. Recently, Bassan
demonstrated the possibility of extracting biological informa-
tion from breast tissue samples ﬁxed to standard glass
microscope slides that could similarly be implemented for
cytology workﬂows.81 In particular, Bassan demonstrated that
standard glass microscope slides are infrared transparent at
3 700−2 000 cm−1 wavenumber regions, allowing the acquis-
ition of certain vibrations including νs/as(CH3), νs/as(CH2),
νs/as(NH), and amide A modes pertinent to the identiﬁcation
of biological molecules (Figure 3). Furthermore, Rutter has
shown that thin glass coverslips allow spectral acquisition in
the amide I and lipid regions that facilitate separation between
diﬀerent cancerous cell types94 and is another important
example of how spectroscopists must adapt to the demands of
cytopathology departments if clinical translation to health care
is to be achieved.
Figure 3. Schematic shows that standard laboratory glass microscope
slides are infrared transparent at 3 700−2 000 cm−1, which allows
identiﬁcation of vibrational modes pertinent to the identiﬁcation of
speciﬁc biological molecules. Reproduced and adapted with
permission from ref 79. Copyright 2014 American Chemical Society.
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■ INFRARED SPECTROSCOPY FOR BACTERIA
Infrared spectroscopy represents an attractive technology for
clinical translation to microbiology laboratories where
chemical proﬁling of prokaryotic cells may facilitate classi-
ﬁcation of clinical pathogenic bacteria. Today, clinical
microbiologists employ a wide range of techniques to detect
pathogenic bacteria, including microscopy, serology, microbial
cultures, and immunological and molecular testing. Preliminary
microscopic gram staining of bacteria is subjective, inﬂuenced
by previous antibiotic administration and cannot identify
individual species, thus requiring additional testing.95 Serology
based tests for several infectious diseases suﬀer from cross-
reactivity, poor speciﬁcity, and lengthy seroconversion times
prevent applicability to acute clinical settings.96 Similarly,
microbial cultures depend on bacterial multiplication and
puriﬁcation strategies to study virulence, antibiotic suscepti-
bility, and genomic and proteomic properties, which is time-
consuming, laborious, requires specialized staﬀ, and has limited
applicability to <1% of microbes.97,98 While emergence of
immunological and molecular techniques have revolutionized
clinical microbiology, both technologies are inherently
expensive, with antigen−antibody methods suﬀering from
low sensitivities96 and nucleic acid testing time-consuming and
labor intensive.99 Hence, there is a clear clinical need for low-
cost, high-throughput, and sensitive and speciﬁc modalities to
detect pathogenic bacteria for early clinical diagnosis and
timely therapeutic intervention, to which infrared spectroscopy
may be invaluable in the near future.
Infrared spectroscopy has demonstrated signiﬁcant diag-
nostic capabilities for microbiology, with early studies showing
accurate identiﬁcation of bacterial pathogens, including the
clinically important Staphylococcus, Streptococcus, and
Aeromonas species, based on distinctive spectral signatures
within deﬁned wavenumber regions.100,101 Thereafter, several
groups reported identiﬁcation of numerous pathogenic bacteria
by analyzing spectra with advanced chemometrics, including
Campylobacter,102 Escherichia,103 Bacillus,104 Pseudomo-
nas,105 and Salmonella,106 with classiﬁcation to genus, species,
or strain taxonomies. Recently, Sharaha has further shown
potential to evaluate the sensitivity of Escherichia coli strains to
speciﬁc antibiotic drugs,107 which is particularly relevant given
current public health challenges concerning antibiotic resist-
ance.108 Additionally, infrared spectroscopy has demonstrated
reduced analysis time compared to current clinical practice
typically at 1−5 days for bacteria,109 with small microcolonies
of bacteria cultured and analyzed in 6−8 h.48
Yet, despite the signiﬁcant potential of infrared spectroscopy
for microbial detection, the technology has not witnessed
translation to clinical laboratories, which poses the complex
question: why? One major challenge preventing translation of
infrared spectroscopy to the microbiology setting concerns the
sensitivity of the technique to diﬀerent microbial culture
environments, such as culture media, temperature, and
inoculation time, which alongside diﬀerent instrumentation
and computational methods may lead to variable analytical
performance.110 Hence, standardization protocols and con-
tinued development of infrared bacterial databases must be
Figure 4. (a) FT-IR mean spectra of the RKI test sample comprising three genera of Gram-positive bacteria (Bacillus, Enterococcus, and
Staphylococcus) and three genera of Gram-negative bacteria (Citrobacter, Pseudomonas, and Escherichia). (b) Characterization of microcolony
imprints using FT-IR-microscopy for classiﬁcation of RKI test samples to diﬀerent taxonomies. Reproduced and adapted with permission from ref
110. Copyright 2018 American Chemical Society.
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realized to validate results and enable analytical conﬁdence
across microbiology laboratories. Additionally, the vast
majority of studies have employed traditional FT-IR
techniques on microbial culture isolates, which does not
circumvent current time-consuming and laborious isolation
and puriﬁcation procedures. Interestingly, Ngo-Thi showed
FT-IR-microscopy could identify bacterial species from mixed
culture with successful classiﬁcation from diverse micro-
colonies of 22 Staphylococcus species, although the linear
mapping approach is inherently slow for routine clinical
testing.111 Recently, Lasch showed FT-IR-microscopy could
accurately classify mixed Gram-positive and Gram-negative
genera to diﬀerent taxonomies by evaluating hyperspectral
images and artiﬁcial neural networks (ANNs), with spectral
collection utilizing FPA detectors enabling signiﬁcantly faster
clinical analysis.112 In particular, Lasch found distinct spectral
diﬀerences between pathogenic bacterial taxonomies, with
variations in ν(CH2) and ν(CH3) vibrations at 2800−3000
cm−1, the ester ν(CO) vibration at 1700−1760 cm−1,
δ(CH2) and δ(CH3) vibrations at 1370−1490 cm−1 and
polysaccharide contributions at 900−1200 cm−1 pertinent to
discrimination, with classiﬁcation highlighted by separate
colors in ANN images (Figure 4a,b). However, both FT-IR-
microscopy studies described employ reﬂectance and/or
transmission techniques, respectively, with substrates cost
prohibitive for clinical translation. Therefore, health economic
studies that clearly demonstrate cost eﬀectiveness for speciﬁc
microbiology applications need to be conducted before
translation to microbiology laboratories can be realized.
Interestingly, Kirkwood demonstrated microarray printing of
microbial cultures enabling high-throughput analysis of
multiple microcolonies on a conventional substrate, which
reduces analysis cost per slide and possibly could enable future
adoption of FT-IR-microscopy for mixed culture applica-
tions.113 Alternatively, future endeavors utilizing traditional
FT-IR techniques for mixed culture classiﬁcation would
represent a signiﬁcant step toward clinical translation due to
overall sampling simplicity, although it is recognized to be
technically challenging because of the signiﬁcant overlap of
bacterial spectra.114
Another barrier for clinical translation of infrared spectros-
copy to microbiology laboratories concerns current clinical
sample throughput capabilities since present studies primarily
utilize transmission or ATR-FT-IR modalities with consecutive
transfer and analysis of bacterial cultures. However, Scholz
recently demonstrated high throughput capabilities for FT-IR
analysis of Escherichia coli species, where microliter volumes of
microbial cultures were analyzed with transmission on 96-well
zinc selenide microtiter plates.115 Similarly, Kohler showed
high-throughput transmission FT-IR of microcultivated yeast
samples on infrared transparent 384-well microtiter plates116
and represents a promising approach for future clinical
translation given microtiter plate technology is well established
for automated workﬂows.
Integration of infrared spectroscopy with microﬂuidics could
also be signiﬁcant for future clinical translation to microbiology
cell suspension applications since coupling of both techniques
allows precise control of optical path lengths and minimization
of spectral contributions from strong infrared absorbing
solvents. Recently, Holman demonstrated an integrated
infrared spectroscopic and microﬂuidic platform for real-time
monitoring of Escherichia coli within bioﬁlm structures.117
While the study utilized synchrotron radiation which is not
conducive to clinical laboratory testing, it is conceivable that
QCL sources could in the future facilitate observation of the
dynamic biochemical behavior of bacteria at discrete
frequencies in their native environments. Similarly, Pousti
demonstrated a microﬂuidic device that utilized ATR-FT-IR
for in situ monitoring of Pseudomonas bioﬁlms,118 and given
the portability and miniaturization capabilities of both
technologies, it is easy to envisage clinical translation of
combined approaches for future detection of pathogenic
bacteria in point-of-care settings.
■ INFRARED SPECTROSCOPY FOR NOVEL
BIOMARKER DISCOVERY AND PERSONALIZED
MEDICINE
Infrared spectroscopy represents a powerful investigative tool
for understanding the molecular landscape and chemical
pathologies of various clinical diseases. Speciﬁcally, synchro-
tron infrared sources coupled to FT-IR microscopy has shown
immense potential for clinical research where the photon ﬂux
density is 100−1000 times greater than traditional Globar
sources enabling diﬀraction limited spatial resolution and high
signal-to-noise.119 Consequently, synchrotron FT-IR micros-
copy may be employed for nondestructive interrogation of
biological matter where small apertures down to 3 μm × 3 μm
facilitate subcellular biochemical studies.120 To date, synchro-
tron FT-IR microscopy has demonstrated signiﬁcant clinical
applicability to investigate multiple diseases,121,122 including
cancer,123 with a wide range of studies from cytokinesis of
prostate cells124 to apoptosis of glioma cells.125 Hence,
synchrotron FT-IR is set to play an increasingly vital role for
clinical research, and while instrumentation is not conducive to
health care settings, it may inform future clinical decisions and
diagnosis with conventional medical modalities. To this extent,
Ducǐc ́ utilized synchrotron FT-IR to understand the chemical
changes of astrocytes associated with genetic mutations of the
metallo-enzyme copper−zinc superoxide dismutase (SOD1)
implicated in familial amyotrophic lateral sclerosis, a common
type of motor neuron disease (Figure 5).126 In particular,
Ducǐc ́ found localized enhancement of νs/as(CH2), νs/as(CH3),
and ν(CO) vibrations revealed increased concentrations of
lipids in the central regions of ALS astrocytes and signiﬁcant
lipid acyl chain saturation, neither of which were observed in
nontransgenic littermate (Ngs) control astrocytes. Further-
more, diﬀerences in amide I and II vibrations reﬂected
increased antiparallel β-sheet protein secondary structures,
while absence of νasN(CH3)3 vibrations indicate disruption of
choline metabolism in ALS astrocytes. Importantly, these
spectral signatures have enabled identiﬁcation of large
aggregates of lipid vesicles and SOD1 proteins, lipid
peroxidation, and metabolic choline alterations, all of which
may allow future biomarker discovery and development of
novel therapeutic strategies. Similarly, Pijanka employed
synchrotron FT-IR microscopy to interrogate isolated nuclei
of CALU-1 lung cancer cells where changes in lipid, protein,
and DNA signatures may provide spectral biomarkers toward
cancer diagnosis.92 Furthermore, Nakamura showed synchro-
tron FT-IR microscopy has the capacity to establish spectral
biomarkers for adult stem cells in human corneal epithelium
that may help identify their in situ location for clinical
applications,127 with both studies highlighting the potential of
synchrotron FT-IR for biomarker discovery that could
inﬂuence future clinical workﬂows. Recently, Siddique
demonstrated signiﬁcant potential of synchrotron FT-IR
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microscopy for evaluation of clinical therapeutics, where K562
leukemia cells were analyzed for sensitivity toward Nilotinib,
with the view to discovering spectral biomarkers that may in
the future enable clinicians to determine patient suitability to
speciﬁc chemotherapy agents.128 Similarly, Rutter, expanding
on previous FT-IR microscopy studies that analyzed responses
of CALU-1 lung cancer cells to gemcitabine,129 employed
synchrotron FT-IR microscopy to identify spectral biomarkers
indicative of cell sensitivity or resistance to gemcitabine130 and
underlines the future potential of infrared spectroscopy toward
personalized medicine strategies.
It is clear that infrared spectroscopy has a multitude of
applications within the clinic and is applicable to all clinical
samples types (e.g., bioﬂuids, tissue, and cells) providing high
ﬁdelity data that can aid in clinical decision making. Armed
with the methodological advances described above the impact
within healthcare has the potential to be disruptive to the
current approach and can provide reduced mortality and
morbidity and enhanced quality of life for patients around the
globe. In addition, the new and exciting additions to the
technological stability of IR instrumentation with the recent
use of QCL, which allows the use of non-liquid nitrogen
cooled detectors and supercontinuum sources, the develop-
ment of optical photothermal infrared (OPTIR) by companies
such as Photothermal Spectroscopy Corp. and the methodo-
logical varieties for nanoscale based infrared analysis will
undoubtedly have a huge impact in this area when the wealth
of research using traditional IR can be developed within these
techniques. IR has clinical ability and is ready for translation.
The particular developments shown above and the move
toward an entrepreneurial approach to clinical translation
within the spectroscopic community is direly needed, in our
opinion, to enable the ﬁrst product(s) to be released on the
market. Following this, the lessons learnt and communicated
will enable a wealth of clinically appropriate spectroscopic
technology to develop underpinned by close collaboration
between clinicians, scientists, entrepreneurs, and investors to
change patient processes and management for patient beneﬁt.
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